A profound med-tech breakthrough

Livewire Exclusive

Livewire Markets

Catherine Wood, CEO and CIO at ARK Investment Management (ARK), invests on the cutting edge of robotics, energy storage, next-generation internet and blockchain technology. However it is in the field of genomic sequencing that she tell us: “Something is happening that is more profound than I’ve ever experienced”. 


Key points

  • A revolutionary gene-editing technology has emerged that may potentially hold the cure for some diseases. The first human trials in the US are taking place this year in cases of paediatric blindness.
  • Another technology that ARK is backing can turn a patient’s immune system against cancerous cells. It is yielding promising results in non-Hodgkin’s lymphoma. 

Further insights 

Nikko AM Australia  is pleased to bring the ARK Investment Management strategies and capabilities to Australia. Click here to find out more

ARK Investment Management is a Nikko Asset Management strategic partner. This material is issued in Australia by Nikko AM Limited ABN 99 003 376 252, AFSL 237563.


2 contributors mentioned

Livewire Exclusive
Livewire Markets

Livewire Exclusive brings you exclusive content from a wide range of leading fund managers and investment professionals.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment